STAT+: Human Cell Atlas leader’s tie to 10x Genomics raises conflict-of-interest questions

A decade since its founding, the International Human Cell Atlas Consortium is hosting a high-profile meeting in Boston this week, with panels featuring more than two dozen prominent academics and biotech industry leaders, including Genentech’s Aviv Regev, David Altshuler of Vertex Pharmaceuticals, and Eric Lander from the Broad Institute. The event, which is expected to draw hundreds of scientists from across the globe, comes at an inflection point in the HCA’s ambitious aim to build a comprehensive reference map of all the different types of cells that make up a human body. 

Later this year, the HCA expects to deliver a first draft — the completion of single-cell atlases across all of the major organs and tissues — that promise to boost researchers’ understanding of how the body works. So far the HCA has focused on building a reference of healthy cells and the genes they express. In its next phase, it plans to tackle disease, and that means amassing knowledge about where particular cells are located, who their neighbors are, and who they’re communicating with — a rapidly emerging field known as spatial biology.

It’s embarking on this expansion when the field is awash in new technology options from companies like Vizgen, Bruker, Illumina, Takara Bio, Bio-Techne, and 10x Genomics, a Bay Area company whose single-cell RNA sequencing technology was the workhorse of the HCA’s first phase. Scientists who want to join this effort will be faced with decisions about which commercially available solutions to use. 

Continue to STAT+ to read the full story…

Opinion: I’m an Alzheimer’s specialist. I still missed it in my own father

For years, my family noticed my father making small mistakes. We did what most families do: We explained it away. The stress of his schedule, we said — he was working constantly, under real pressure.

But when he came to meet my second daughter the week after she was born, I could no longer explain it away. As he entered the gate to our yard, he looked down at our small dog — an animal who had been a fixture in my home for years, a face he should have known well — and his expression went uncertain. Then he asked if I had gotten a new dog.

Read the rest…

Opinion: Congress must reauthorize the Pandemic and All-Hazards Preparedness Act

The Trump administration has taken important steps to strengthen America’s national health security by preserving the Administration for Strategic Preparedness and Response, known as ASPR, within the Department of Health and Human Services and recently nominating a new assistant secretary to guide the agency.

Congress should now build on that momentum by swiftly confirming the administration’s nominee and reauthorizing the law that provides ASPR’s authorities, the Pandemic and All-Hazards Preparedness Act.

Read the rest…

EEG Biomarkers for ADHD Stimulant Treatment

Conditions: ADHD

Interventions: Drug: methylphenidate HCl; Drug: Mixed amphetamine salts extended release

Sponsors: Boston Children’s Hospital; Seattle Children’s Hospital; Tris Pharma, Inc.

Not yet recruiting

Examining the Efficacy of a Telehealth-Based Virtual Reality Clinic in Treating Adults With Specific Phobia: Feasibility Randomized Controlled Trial

Background: Virtual reality (VR) has the potential to enhance telemental health care (TMH) by enabling accessible, engaging, and personalized treatment from home. Although VR is well-supported for in-person treatment, evidence for telehealth-based VR is limited. Moreover, no prior research has demonstrated the feasibility of therapists and clients conducting therapy sessions remotely within a shared (ie, multiuser) VR experience. Objective: The primary objective of this study was to evaluate the feasibility of conducting a randomized controlled efficacy trial (RCT) comparing exposure therapy delivered via Doxy.me VR (Doxy.me Inc)—a multiuser, telehealth-based VR app—to standard TMH in adults with clinically elevated fear of dogs, snakes, or spiders. A secondary objective was to preliminarily examine clinical (ie, specific phobia symptom severity) and treatment-related outcomes (ie, therapeutic alliance, client satisfaction, system usability, presence, cybersickness, and treatment fidelity). Methods: This study used a single-site, fully remote, parallel, feasibility RCT design. Participants were randomly assigned using a 1:1 ratio to receive 12 weekly exposure therapy sessions over 3 months, delivered via either standard TMH or Doxy.me VR. Assessments were conducted at baseline, each session, midtreatment, and posttreatment. All therapy sessions were audio recorded, 20% of which were randomly selected and rated for treatment fidelity. Feasibility benchmarks during the 12-month trial included: (1) enrolling 30 participants during Months 1‐9 of the trial; (2) collecting 70% of midtreatment self-report data; (3) collecting 70% of posttreatment self-report data; (4) collecting 70% of weekly self-report data; and (5) achieving treatment fidelity ≥80%. Between-group differences in clinical treatment-related outcomes also were examined preliminarily. Results: A total of 54 participants were enrolled between October 25, 2023 and July 26, 2024, and randomly assigned to the Doxy.me VR (n=29) and TMH (n=25) conditions, exceeding our recruitment target by 180%. Among the 30 participants targeted for completion, data were obtained from 29 (96.7%) at midtreatment and 28 (93.3%) at posttreatment. Participants completed 86.5% (180/208) of weekly self-report assessments. Treatment fidelity was 90% based on ratings of 41 session recordings. There were no significant between-group differences in clinical outcomes (all >.05) or most treatment-related outcomes. However, client satisfaction improved significantly more for the Doxy.me VR condition compared to TMH (=.04). Power analyses indicated that a sample of 160 participants would ensure adequate power for a fully powered trial. Conclusions: Telehealth-based, multiuser, synchronous VRET is feasible and shows preliminary evidence of efficacy. These findings are promising, and opportunities to improve procedures identified in this feasibility trial will directly inform the protocol for a fully powered RCT evaluating telehealth-based VR and its potential to improve treatment of mental health disorders. Trial Registration: ClinicalTrials.gov NCT06302868; https://clinicaltrials.gov/study/NCT06302868 International Registered Report Identifier (IRRID): RR2-10.2196/65770

Why do South Koreans love AI so much?

This story originally appeared in The Algorithm, our weekly newsletter on AI. To get stories like this in your inbox first, sign up here.

When I landed in Seoul after a grueling 12-hour flight from San Francisco, I walked through an unmanned immigration checkpoint, where a machine scanned my face and passport. On the subway home, people were glued to their phones (powered by flawless 5G even underground), as we raced past platforms lined with LED screens of ads celebrating K-pop idols’ birthdays. When I got off the station in Gangnam, a cartoon-eyed robot on wheels was waiting patiently at a crosswalk to deliver someone’s dinner. Internet cafés dotted the sidewalks, crammed with teenagers playing computer games, maybe hoping to become the next legendary pro gamer.

I stood at a bus stop with interactive touch screens showing real-time bus schedule updates. It will soon become an “AI bus stop,” the Gangnam district announced in June, with a kiosk that answers riders’ questions in multiple languages. The news didn’t surprise me. Having grown up in the city, I’ve watched Seoul transform from a scrappy boomtown into the gleaming tech capital it is today.

South Korea loves AI.

While a public backlash against AI is brewing across the US, South Koreans are optimistic. Only 16% say they are more concerned than excited about AI—the lowest of any of the 25 countries surveyed by the Pew Research Center—while 50% of Americans were more worried than excited. A majority of Koreans use AI every day, either as a sort of personal assistant or to do tasks at work, according to surveys by the Ministry of Culture, Sports, and Tourism and Korea Chamber of Commerce and Industry.

One of the most wired countries in the world, South Korea loves to street-test every new technology on the block—AI webcomics, virtual K-pop idols, and humanoid monks. And the appetite for experimentation doesn’t stop with ordinary citizens. Government agencies are early adopters too, deploying AI textbooks in schools and AI eldercare robots in welfare centers. South Koreans share a deep conviction that embracing technology is integral to modernizing the country and cementing its place in the global order. Their fascination with AI is just the latest incarnation of that ethos—and it’s making them anxious to stay ahead.

Engineered enthusiasm

All this techno-optimism has largely been engineered by South Korea’s national agenda to make AI a motor of economic growth. “The South Korean government has designated an AI-powered Fourth Industrial Revolution as the country’s path forward and aggressively promoted and invested in it,” says Chihyung Jeon, a professor of science and technology policy at the Korea Advanced Institute of Science and Technology. “South Koreans have consistently and relentlessly been told by the government about AI’s potential to create a better future.”

As South Korea rose from the ashes of the Korean War, technology lifted the nation from poverty into an economic powerhouse. In the 1970s, South Korea manufactured steel and ships, then semiconductors in the 1980s, broadband in the 1990s, and smartphones in the 2000s. Today, Samsung and SK Hynix supply most of the world’s high-bandwidth memory chips, which power the cutting-edge Nvidia hardware used to train AI models. South Korea’s economy now orbits these two semiconductor giants: The country’s main equity index, Kospi, surged to record highs in 2026, powered by the soaring share prices of both companies, each valued above $1 trillion.

Lee Jae-myung, president of South Korea, has pledged to vault the country into the ranks of the “top three AI powers” alongside the US and China. After taking office in 2025, he launched the Presidential Council on National AI Strategy to help buy massive amounts of computing power and a sovereign AI foundation model project that funds Korean companies to develop homegrown AI models. The government has also supported semiconductor titans, including Samsung and SK Hynix, through generous tax credits and low-interest financing. 

South Korea’s policy posture also prioritizes accelerating AI development over safety considerations. In 2024, South Korea’s legislature passed the AI Basic Act, one of the world’s first comprehensive AI laws, to promote AI development and establish light-touch regulatory guardrails. Seventy percent of South Koreans say advancing science and medicine through AI innovation is a bigger priority than protecting industries through regulation, according to the 2026 Stanford AI Index.

All of that effort might be paying off. The same index ranked South Korea as having the third largest number of notable AI models in the world, based on criteria such as state-of-the-art advancements or high citation rates. For many small countries like South Korea, AI is a chance to punch above their weight.

The blind spots

But that single-mindedness can crowd out critical reflection on AI’s broader societal impacts. “Because the national agenda on AI prioritizes economic development,” says Jeon, the professor of science and technology policy, “there isn’t much reflection on the social, political, ethical dimensions of the technology.” In 2025, the South Korean government faced a fierce backlash for rolling out AI textbooks riddled with factual inaccuracies and data privacy risks without testing them first in a pilot program to evaluate how they affect student learning.

And despite their optimism, South Koreans are still worried that AI could displace them from their jobs. After Hyundai announced in January that it will deploy Atlas humanoid robots across its car factories, the Hyundai Motor Group union protested vehemently. “Without labor-management agreement, not a single robot using new technology will be allowed to enter the workplace,” the union said. Sixty-four percent of South Koreans fear AI could displace human labor and exacerbate inequality, although 52% believe it could also increase productivity. 

On a recent Friday night in the Seoul Central Market, I went out with my cousins to a pocha, a late-night restaurant that serves fish cakes stacked in neat pyramids. As we clinked our cups of soju cut with beer—the scrappy staple cocktail of every Korean night out—one cousin asked me if I’d asked ChatGPT about my saju, a traditional Korean fortune-telling practice. A 29-year-old insurance agent in Seoul praying for a new job and a boyfriend, she said asking ChatGPT about work and dating was her favorite pastime. She pulled up her phone and punched my birth date into the chatbot. 

Addicted to their screens, trapped between unemployment and dead-end jobs, and priced out of marriage and homeownership, 46% of South Koreans in their 20s have used a chatbot to read their fortunes, according to a survey by Korea Gallup. 

My cousin said she also asks ChatGPT for tips on trading stocks, dreaming big about making bank on her investment accounts into which she’s been pouring her salary. ChatGPT, she believes, is her portal out of reality into a better future.

Despite how fond she is of the chatbot as her shaman and financial advisor, she fears losing her job to AI. She still uses ChatGPT feverishly at work, as all her coworkers do, afraid of falling behind. 

“I sometimes fear AI, but for now, it’s just so useful,” she said.

STAT+: FDA approves Colorado’s plan to import cheaper drugs from Canada

WASHINGTON — The Food and Drug Administration said Monday that it will allow Colorado to import certain prescription drugs from Canada in an effort to bring prices down for residents, making it the second U.S. state to be granted such authorization. 

For more than a quarter of a century, Americans have sought drugs from Canada for relief from the ever-rising costs of medicines, sometimes taking widely publicized bus trips across the border. It wasn’t until 2020, though, that the first Trump administration officially endorsed the practice, when it published a regulation allowing states and Indian tribes to propose import plans. The Biden administration affirmed this rule with an executive order in 2021. And Florida became the first state to earn FDA approval in 2024. 

But state importation programs have proved extremely difficult to carry out, even with bipartisan support. Florida has yet to actually import any drugs from Canada, in part due to pushback from the Canadian pharmaceutical industry and fears the program will affect Canada’s drug supply. In May, the FDA extended its approval by six months to give the state more time to get its program up and running. 

Continue to STAT+ to read the full story…

STAT+: Trump’s obesity drug plan creates a temporary Medicare program that may be hard to end

WASHINGTON — Weight loss drugs will be available to adults 65 and older in Medicare for the first time next month, thanks to a government program that’s supposed to be temporary. It may be difficult to end it.

Medicare is prohibited by law from paying for obesity drugs. The Trump administration is circumventing that law by making the drugs available via a demonstration program.

Initially, Medicare had hoped to push private Medicare insurers to voluntarily cover the drugs via a three-year program called BALANCE, which would have started following a short transitional period. But insurers balked, so the federal government is instead extending the transitional coverage program, called Bridge, until the end of next year.

Continue to STAT+ to read the full story…